110.3475  -1.073 (-0.96%)		09-11 13:27
Open: 113 High: 115 Volume: 109,676		Pre. Close: 111.42 Low: 109.22 Market Cap: 1,619(M)

Short term
Mid term
Targets	6-month :	153.01	1-year :	178.72
Resists	First :	131	Second :	153.01
Pivot price	118.18
Supports	First :	99.74	Second :	80.41
MAs	MA(5) :	114.04	MA(20) :	112.42
	MA(100) :	102.62	MA(250) :	81.88
MACD	MACD :	5.3	Signal :	7
%K %D	K(14,3) :	47.4	D(3) :	54.5
RSI	RSI(14): 51.7
52-week	High :	155.28	Low :	26.19

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INBX ] has closed above bottom band by 24.3%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	114.69 - 115.79	115.79 - 116.46
Low:	104.95 - 106.35	106.35 - 107.19
Close:	109.78 - 112.11	112.11 - 113.52

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Thu, 10 Sep 2026
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com

Thu, 10 Sep 2026
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - stocktitan.net

Thu, 10 Sep 2026
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail

Thu, 10 Sep 2026
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - simplywall.st

Wed, 09 Sep 2026
Director-linked trust plans $57.9K INBX stock sale - stocktitan.net

Wed, 09 Sep 2026
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	15 (M)
Held by Insiders	8.64e+006 (%)
Held by Institutions	23 (%)
Shares Short	3,430 (K)
Shares Short P.Month	0 (K)

EPS	-1.256e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-43.7 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	210.79
EBITDA (p.s.)	-2.80654e+007
Qtrly Earnings Growth	-8.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-132 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0.52
Price to Cash Flow	-112.59

Dividend	0
Forward Dividend	3.22e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.